# Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

> **NCT00776373** · PHASE1,PHASE2 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 4 (actual)

## Conditions studied

- ALL
- Burkitt's Lymphoma
- Lymphoblastic Leukemia
- CML

## Interventions

- **DRUG:** Rapamycin
- **DRUG:** High dose etoposide and cytarabine (HiVAC)

## Key facts

- **NCT ID:** NCT00776373
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2008-12
- **Final completion:** 2009-12
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00776373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00776373, "Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00776373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*